Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Go back to Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance

March 20, 2023 4:08 PM EDT

Exagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.83), $0.06 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $8.66 million.

GUIDANCE:

Exagen Inc. sees Q1 2023 revenue of $9.2-9.7 million, versus the consensus... More